AZ presents competitive Farxiga data in heart failure

Detailed data from AstraZeneca has shown SGLT2 inhibitors developed for Type II diabetes may be even more efficacious in heart failure than existing therapies.

Joris Silon, SVP of cardiovascular, renal and metabolism at AstraZeneca plc (LSE:AZN; NYSE:AZN), said the data may give Farxiga dapagliflozin a competitive commercial profile compared

Read the full 483 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE